Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Rheumatoid arthritis

Blocking the immune system in rheumatoid arthritis

Rheumatoid arthritis is caused by the immune system attacking the body. It afflicts about 1% of people in the UK and is now treated with a variety of biologic drugs that dampen the immune system in different ways.

Infographic showing how the immune system blocks rheumatoid arthritis, drug development and treatment pathways

Blocking the immune system in rheumatoid arthritis

Download a PDF of the full infographic

Infographic showing the drug targets in rheumatoid arthritis

Drug targets in rheumatoid arthritis

Source: Summary of product characteristics and Nature

Oral disease-modifying anti-rheumatic drugs (DMARDs), the mainstay of rheumatoid arthritis treatment, were the first drugs available that affected the immune system. But over the past fifteen years, a multitude of new biologic therapies have hit the market, which target specific parts of the immune system. New small molecules are also in development that target intracellular immune signalling

Diagram showing treatment pathway for rheumatoid arthritis

Treatment pathway for rheumatoid arthritis

Source: National Institute for Health and Care Excellence (NICE)

Early targeted therapy to rapidly control disease activity in rheumatoid arthritis (RA) is crucial to limiting long-term joint damage. A range of drugs are approved by the National Institute for Health and Care Excellence (NICE) for use within the NHS

Timeline showing drug development for rheumatoid arthritis

Timeline of drug development for rheumatoid arthritis

Source: NICE, British National Formulary, Arthritis Research and Therapy

The first big breakthrough in RA treatment was methotrexate. Since then, numerous biologics have been approved by the European Medicines Agency for use in combination with methotrexate. The prices are high but efficacy is good for patients who have failed on methotrexate and other oral DMARDs alone. The first biosimilars were approved in 2013, introducing more price competition to the biologics market.

  • This article was updated on 1 June 2016 to clarify that rituximab is known as Mabthera and is manufactured by Roche.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201090

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Infographic showing how the immune system blocks rheumatoid arthritis, drug development and treatment pathways
  • Infographic showing the drug targets in rheumatoid arthritis
  • Diagram showing treatment pathway for rheumatoid arthritis
  • Timeline showing drug development for rheumatoid arthritis

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.